All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Gout is a common inflammatory arthropathy caused by the deposition of monosodium urate crystals in joints and soft tissues. In the general population, the prevalence of gout varies worldwide from 0.1% to approximately 10% and incidence rates vary from 0.3 to 6 cases per 1,000 person-years \[[@pone.0210487.ref001]\]. In addition to causing excruciating arthritic pain, gout is associated with premature death, classically explained by a high frequency of comorbid conditions, especially renal and cardiovascular diseases \[[@pone.0210487.ref002]--[@pone.0210487.ref004]\]. Gout is associated with a progressive functional impairment, reduced quality of life, lost productivity and increased mortality \[[@pone.0210487.ref005],[@pone.0210487.ref006]\]. Recent observational studies implicate both hyperuricaemia and gout as possible risk factors for progression of chronic kidney disease (CKD) suggesting that the treatment of these conditions may lead to measurable clinical benefits \[[@pone.0210487.ref007],[@pone.0210487.ref008]\]. Several small clinical trials have found that treatment with Urate-Lowering Therapy (ULT) reduced the progression of kidney disease \[[@pone.0210487.ref009],[@pone.0210487.ref010]\]. Furthermore, a recent meta-analysis of clinical trials with over 1, 200 patients found that treatment with ULT significantly reduced the risk of major renal and cardiovascular events \[[@pone.0210487.ref011]\]. This emerging evidence would suggest that treatment and control of gout is especially important among patients with impaired kidney function.

Few studies have examined the burden of gout among individuals with impaired kidney function in the general population or with CKD within the health system. A report from Krishnan using data from the 2009--2010 National Health and Nutrition Examination Survey (NHANES) in the US found that the prevalence of self-reported gout increased from 2.9% in patients with normal renal function to 33.3% among those with glomerular filtration rate (eGFR) \< 30 ml/min/1.73m^2^. Adjusting for confounding, individuals with severe renal impairment had a 6-fold higher prevalence of gout compared to those with normal kidney function \[[@pone.0210487.ref012]\]. Data from the German Chronic Kidney Disease (GCKD) cohort, a prospective observational study of 5,085 patients, found a prevalence of 24.3% among patients with pre-existing CKD which increased to 35.6% among those with GFR \< 30 ml/min/1.73m^2^ \[[@pone.0210487.ref013]\]. These studies would suggest that gout is highly prevalent among patients with pre-existing CKD and may contribute significantly to morbidity from arthropathy and accelerated kidney disease progression. Despite these studies there are several unanswered questions with regard to the burden of gout and its management among patients with CKD in the health system. For example, it is unclear to what extent patients with gout who attend specialist renal clinics are treated with ULT and whether treatment rates vary across stage of CKD.

Given the paucity of data on the burden and management of gout in health systems we conducted a multicentre cross--sectional study to determine the prevalence of gout and concurrent treatment strategies among CKD patients within the Irish health system.

Materials and methods {#sec006}
=====================

Study design {#sec007}
------------

This study was a multicentre cross-sectional study of adult patients with CKD treated at 18 adult specialist nephrology clinics during the first 2 weeks of December 2012 and 2013. All nephrology clinics were invited to participate in the audit and a consecutive sampling approach for patient selection was adopted. The clinics were geographically dispersed across six health regions in the Republic of Ireland (West, Midwest, Northwest, Midlands, East and Southeast). Patients less than 18 years of age or receiving dialysis were excluded. A standardised data collection tool was used to capture anonymised clinical information from medical case records, laboratory information systems and physician clinic letters. Demographic and clinical characteristics were captured including primary cause of kidney disease, comorbid medical conditions, prescribed medications and laboratory values recorded within the previous 3 months \[or within 6 months for specific laboratory values for iron indices, parathyroid hormone (PTH), lipids and haemoglobin A1c (HbA1c)\]. The study was approved by the Ethics Committee of University Hospital Limerick.

Definition of gout {#sec008}
------------------

Gout was defined as the presence of a documented clinical diagnosis of gout on medical case records and/or physician clinic letters or if the patient was receiving ULT. The Estimated Glomerular Filtration Rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation \[[@pone.0210487.ref014]\] and CKD was classified according to the Kidney Disease Improving Global Outcomes (KDIGO) guidelines \[[@pone.0210487.ref015]\]. The following eGFR categories were defined: ≥ 60 ml/min/1.73 m^2^ (Stages 1--2), 30--59 (Stage 3) and \<30 (Stages 4--5).

Statistical methods {#sec009}
-------------------

Descriptive statistics were calculated for continuous variables (reported as mean values and standard deviations or median and IQR where appropriate) and categorical variables (reported as numbers and percentages). Comparisons across groups were made using Fisher's exact tests for categorical variables and Kruskal-Wallis test for continuous variables. Multivariable logistic regression models were fitted to explore the associations of demographic and clinical factors with prevalent gout. Sequential age, and age and sex adjusted models were developed to examine relationships. The explanatory variables included age modelled as 5-year intervals, sex, comorbid medical conditions, laboratory values recorded prior to clinic visit, and prescribed medications. A final multivariate model was constructed to identify the relative contributions of demographic, clinical and treatment factors with the presence of gout. Model performance was assessed using the c-statistic and the adequacy of the logistic models was tested using the Hosmer and Lemeshow goodness-of-fit test. Associations were expressed as odds ratios (ORs) and 95% confidence intervals (CIs) and all analyses were performed using R statistical software \[[@pone.0210487.ref016]\].

Results {#sec010}
=======

Baseline characteristics of the study population {#sec011}
------------------------------------------------

[Table 1](#pone.0210487.t001){ref-type="table"} outlines the basic characteristics of the study population by CKD stage. The majority were men (55.2%), white Irish (95%) and the average age was 58.2 (SD 16.9). The average eGFR was 48.4 (SD 27.7) ml/min/1.73 m^2^. The principal causes of CKD were hypertension (26.8%), glomerulonephritis (18.1%) and diabetes (12%), although for a large proportion the primary cause was classified as unknown in 13.6%.

10.1371/journal.pone.0210487.t001

###### Baseline characteristics of the study population by stage of CKD.

![](pone.0210487.t001){#pone.0210487.t001g}

  --------------------------------------------------------------------------------------------------------------------------
  Variable                                n     Overall Cohort\   Stage 1--2\    Stage 3\        Stage 4--5\     *P*-value
                                                (n = 522)         (n = 142)      (n = 176)       (n = 139)       
  --------------------------------------- ----- ----------------- -------------- --------------- --------------- -----------
  **Demographic**                                                                                                

   Age mean (SD)                          515   58.2 (16.9)       48.8(14.5)     60.3(15.1)      66.3(15.7)      \<0.001

  Sex                                                                                                            

   Men (%)                                283   (55.2)            78.0 (54.9)    106.0 (60.2)    77.0 (55.4)     

   Women (%)                              230   (44.8)            64.0 (45.1)    70.0 (39.8)     62.0 (44.6)     0.568

  **Race (%)**                                                                                                   

   White Irish                            479   (95.0)            126.0 (91.3)   168.0 (96.6)    132.0 (96.4)    0.051

   White Irish traveller                  2     (0.4)             1.0 (0.7)      0.0 (0.0)       0.0 (0.0)       0.054

   White other                            12    (2.4)             2.0 (1.4)      5.0 (2.9)       4.0 (2.9)       0.054

   Asian                                  2     (0.4)             1.0 (0.7)      1.0 (0.6)       0.0 (0.0)       0.051

   Other                                  9     (1.8)             8.0 (5.8)      0.0 (0.0)       1.0 (0.7)       0.052

  **Cause of CKD (%)**                                                                                           

   Hypertension                           138   (26.8)            31.0 (21.8)    44.0 (25.0)     48.0 (34.5)     0.045

   Diabetes                               62    (12.0)            12.0 (8.5)     25.0 (14.2)     23.0 (16.5)     0.105

   Glomerulonephritis                     93    (18.1)            35.0 (24.6)    26.0 (14.8)     21.0 (15.1)     0.052

   Autosomal dominant PKD                 33    (6.4)             7.0 (4.9)      16.0 (9.1)      7.0 (5.0)       0.253

   Hereditary nephritis                   13    (2.5)             5.0 (3.5)      6.0 (3.4)       1.0 (0.7)       0.257

   Other cause of CKD                     168   (32.6)            53.0 (37.3)    58.0 (33.0)     43.0 (30.9)     0.496

   Not known                              70    (13.6)            16.0 (11.3)    18.0 (10.2)     23.0 (16.5)     0.231

  **Biopsy (%)**                                                                                                 

  Native Kidney biopsy                    75    (14.4)            27.0 (19.0)    26.0 (14.8)     18.0 (12.9)     0.363

  **Comorbid Conditions (%)**                                                                                    

   Gout                                   78    (16.6)            9.0 (7.5)      29.0 (17.8)     31.0 (22.8)     0.003

   Diabetes                               106   (22.6)            21.0 (17.6)    38.0 (23.2)     38.0 (27.9)     0.148

   Hypertension                           370   (78.7)            87.0 (73.1)    131.0 (79.9)    114.0 (83.8)    0.108

   Cancer                                 33    (7.0)             9.0 (7.6)      13.0 (7.9)      9.0 (6.6)       0.919

   Heart failure                          22    (4.7)             2.0 (1.7)      7.0 (4.3)       10.0 (7.4)      0.105

   Thyroid disease                        48    (10.2)            7.0 (5.9)      19.0 (11.6)     18.0 (13.2)     0.124

   Stroke or Transient ischaemic attack   22    (4.7)             4.0 (3.4)      7.0 (4.3)       9.0 (6.6)       0.483

   Chronic obstructive airways disease    22    (4.7)             4.0 (3.4)      7.0 (4.3)       8.0 (5.9)       0.607

   Peripheral vascular disease            38    (8.1)             4.0 (3.4)      17.0 (10.4)     15.0 (11.0)     0.042

   Coronary heart disease                 75    (16.0)            11.0 (9.2)     26.0 (16.0)     33.0 (24.3)     0.005

   Obesity                                28    (6.0)             5.0 (4.2)      8.0 (4.9)       12.0 (8.8)      0.262

   Hypercholesterolemia                   127   (27.1)            28.0 (23.3)    48.0 (29.4)     43.0 (32.1)     0.287

   Depression                             20    (4.3)             6.0 (5.0)      6.0 (3.7)       7.0 (5.1)       0.791

   Arthritis                              27    (5.7)             6.0 (5.0)      11.0 (6.7)      6.0 (4.4)       0.689

   Osteoporosis                           30    (6.4)             7.0 (5.9)      16.0 (9.8)      4.0 (2.9)       0.053

   Current or ex-smoker                   52    (11.1)            15.0 (12.6)    20.0 (12.2)     12.0 (8.8)      0.583

  **Physical Measurements**                                                                                      

   Weight (kg)                            397   80.7 (17.5)       79.8 (15.9)    79.8 (17.6)     82.2 (19.5)     0.748

   Pulse (beats/min)                      293   75.2 (16.3)       75.6 (13.1)    73.6 (13.6)     75.7 (19.3)     0.473

   Systolic BP (mmHg)                     481   137.7 (19.6)      131.8 (16.6)   138.5 (19.0)    141.7 (21.7)    \<0.001

   Diastolic BP (mmHg)                    481   77.7 (13.3)       78.7 (13.8)    77.7 (12.9)     76.7 (12.3)     0.302

  **Urine tests**                                                                                                

   Protein: creatinine ratio              136   136.0 (246.8)     49.0 (71.3)    150.1 (348.0)   209.7 (226.3)   \<0.001

   Albumin: creatinine ratio              51    101.9 (214.9)     22.7 (28.1)    93.4 (239.2)    208.2 (280.0)   0.004

  **Prescribed Medications (%)**                                                                                 

   ACE-I                                  114   (21.8)            37.0 (26.1)    45.0 (25.6)     21.0 (15.1)     0.040

   ARB                                    93    (17.8)            27.0 (19.0)    34.0 (19.3)     26.0 (18.7)     0.999

   ACE-I & ARB                            11    (2.1)             3.0 (2.1)      6.0 (3.4)       1.0 (0.7)       0.290

   ACE-I or ARB                           196   (37.5)            61.0 (43.0)    73.0 (41.5)     46.0 (33.1)     0.187

   Aspirin                                169   (32.4)            34.0 (23.9)    59.0 (33.5)     63.0 (45.3)     0.001

   Beta- blocker                          147   (28.2)            36.0 (25.4)    52.0 (29.5)     47.0 (33.8)     0.297

   Calcium blocker                        152   (29.1)            32.0 (22.5)    52.0 (29.5)     50.0 (36.0)     0.045

   Diuretic                               121   (23.2)            17.0 (12.0)    37.0 (21.0)     54.0 (38.8)     \<0.001

   Statin                                 169   (32.4)            36.0 (25.4)    64.0 (36.4)     57.0 (41.0)     0.016

   Vasodilator                            18    (3.4)             2.0 (1.4)      7.0 (4.0)       8.0 (5.8)       0.134

  **Gout-specific medications (%)**                                                                              

  *Urate lowering therapies*              53    (10.2)            5.0 (3.5)      17.0 (9.7)      24.0 (17.3)     \<0.001

   Allopurinol                            49    (9.4)             4.0 (2.8)      15.0 (8.5)      23.0 (16.5)     0.001

   Febuxostat                             4     (0.8)             1.0 (0.7)      2.0 (1.1)       1.0 (0.7)       0.999

  *Acute Flare /flare prophylaxis*                                                                               

   Colchicine                             4     (0.8)             0.0 (0.0)      2.0 (1.1)       0.0 (0.0)       0.340

   Corticosteroid                         21    (4.0)             5.0 (3.5)      11.0 (6.2)      2.0 (1.4)       0.093

   NSAIDs                                 4     (0.8)             2.0 (1.4)      1.0 (0.6)       0.0 (0.0)       0.507
  --------------------------------------------------------------------------------------------------------------------------

PKD, polycystic kidney disease; BP, blood pressure; LDL, low-density lipoprotein; HDL, high-density lipoprotein; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; NSAID, non-steroidal anti-inflammatory medication

Prevalence of gout {#sec012}
------------------

The overall prevalence of gout in the entire cohort was 16.6% and increased significantly from 7.5% in CKD stages 1--2 to 22.8% in CKD stages 4--5, p \< 0.005 ([Fig 1](#pone.0210487.g001){ref-type="fig"}). When gout was defined solely by a medical record diagnosis, the prevalence of gout and by CKD stage followed a similar trend ([S1 Appendix](#pone.0210487.s001){ref-type="supplementary-material"}). The baseline characteristics of the study population by presence or absence of gout are shown in [Table 2](#pone.0210487.t002){ref-type="table"}. Patients with gout were significantly older, predominantly men, and had significantly higher prevalence of coronary disease than those without gout (p\<0.005). Overall frequency of gout increased with advancing age; from 7.5% in patients age \< 44 years to 19.5% for patients age \> 71 years, p\<0.005. Compared to patients without gout, those with gout had significantly lower eGFR values \[36.3 (19.8) versus 48.1 (26.9) ml/min/1.73m^2^ (p \< 0.005) and significantly greater proteinuria \[protein/creatinine ratio 323.4 (571) mg/mmol versus 116.1 (174) respectively, all p\< 0.01\]. Gout patients also experienced significantly lower serum albumin concentrations and significantly higher parathyroid hormone concentrations than those without gout, all p\<0.001.

![Prevalence of gout by CKD stage and age group.\
(a) Prevalence of gout by CKD stage groups (b) Prevalence of gout by age group; a proportional trend test was used to assess the linear trend in the proportion of gout cases across age categories.](pone.0210487.g001){#pone.0210487.g001}
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###### Baseline characteristics of the study population by presence or absence of Gout.

![](pone.0210487.t002){#pone.0210487.t002g}

  ---------------------------------------------------------------------------------------------------------
  Variable                                n     Overall Cohort\   No Gout\        Gout\           P-value
                                                (n = 522)         (n = 393)       (n = 78)        
  --------------------------------------- ----- ----------------- --------------- --------------- ---------
  **Demographic factors**                                                                         

   Age mean (SD)                          515   58.2(16.9)        58.8(16.6)      63.9(13.6)      0.021

  Sex                                                                                             

   Men (%)                                283   (55.2)            214 (54.7)      54 (69.2)       

   Women (%)                              230   (44.8)            177 (45.3)      24 (30.8)       0.024

  **Race (%)**                                                                                    

   White Irish                            479   (95.0)            368 (95.8)      74 (96.1)       0.756

   White Irish traveller                  2     (0.4)             2 (0.5)         0 (0.0)         0.761

   White other                            12    (2.4)             5 (1.3)         3 (3.9)         0.756

   Asian                                  2     (0.4)             2 (0.5)         0 (0.0)         0.76

   Other                                  9     (1.8)             7 (1.8)         0 (0.0)         0.755

  **Cause of CKD (%)**                                                                            

   Hypertension                           138   (26.8)            117 (29.8)      18 (23.1)       0.273

   Diabetes                               62    (12.0)            49 (12.5)       13 (16.7)       0.358

   Glomerulonephritis                     93    (18.1)            66 (16.8)       17 (21.8)       0.328

   Autosomal dominant PKD                 33    (6.4)             26 (6.6)        6 (7.7)         0.805

   Hereditary nephritis                   13    (2.5)             12 (3.1)        1 (1.3)         0.704

   Other cause of CKD                     168   (32.6)            129 (32.8)      22 (28.2)       0.507

   Not known                              70    (13.6)            49 (12.5)       12 (15.4)       0.464

  **Biopsy (%)**                                                                                  

  Native kidney biopsy                    75    (14.4)            60 (15.3)       9 (11.5)        0.485

  **Comorbid Conditions (%)**                                                                     

   Diabetes                               106   (22.6)            87 (22.2)       19 (24.7)       0.656

   Hypertension                           370   (78.7)            306 (78.1)      63 (81.8)       0.544

   Cancer                                 33    (7.0)             27 (6.9)        6 (7.8)         0.807

   Heart failure                          22    (4.7)             19 (4.9)        3 (3.9)         0.999

   Thyroid disease                        48    (10.2)            42 (10.7)       6 (7.8)         0.54

   Stroke or Transient ischaemic attack   22    (4.7)             21 (5.4)        1 (1.3)         0.149

   Chronic obstructive airways disease    22    (4.7)             18 (4.6)        4 (5.2)         0.77

   Peripheral vascular disease            38    (8.1)             32 (8.2)        6 (7.8)         0.999

   Coronary heart disease                 75    (16.0)            52 (13.3)       22 (28.6)       0.002

   Obesity                                28    (6.0)             22 (5.6)        6 (7.8)         0.435

   Hypercholesterolaemia                  127   (27.1)            106 (27.1)      21 (27.3)       0.999

   Depression                             20    (4.3)             20 (5.1)        0 (0.0)         0.057

   Arthritis                              27    (5.7)             23 (5.9)        4 (5.2)         0.999

   Osteoporosis                           30    (6.4)             25 (6.4)        5 (6.5)         0.999

   Current or ex-smoker                   52    (11.1)            44 (11.2)       8 (10.4)        0.999

   Obesity                                28    (6.0)             22 (5.6)        6 (7.8)         0.435

  **Physical Measurements**                                                                       

   Weight (kg)                            397   80.7(17.5)        80.1(16.0)      86.7(23.1)      0.094

   Pulse (beats/min)                      293   75.2(16.3)        74.7(16.2)      76.8(18.2)      0.569

   Systolic BP (mmHg)                     481   137.7(19.6)       137.8(18.8)     140.2(22.5)     0.576

   Diastolic BP (mmHg)                    481   77.7(13.3)        77.6(13.7)      78.6(12.1)      0.826

  **Laboratory Measures**                                                                         

   eGFR (mL/min/1.73m^2^)                 457   48.4 (27.7)       48.1 (26.9)     36.3 (19.8)     0.001

   Haemoglobin (g/dL)                     448   12.6 (1.9)        12.6 (1.9)      12.5 (1.8)      0.289

   Ferritin (ng/L)                        157   253.1 (339.4)     268.6 (361.3)   205.8 (194.9)   0.799

   TSAT ratio (%)                         126   26.7 (13.4)       27.6 (13.9)     22.9 (8.5)      0.184

   Folate (nmol/L)                        95    40.2 (143.7)      38.1 (137.8)    58.6 (190.4)    0.215

   Vitamin B12 (nmol/L)                   119   460.1 (272.1)     471.4 (287.1)   451.2 (160.2)   0.617

   Corrected Calcium (mmol/L)             144   2.3 (0.2)         2.3 (0.1)       2.3 (0.3)       0.528

   Calcium (mmol/L)                       405   2.4 (0.2)         2.4 (0.2)       2.3 (0.1)       0.701

   Albumin (g/L)                          354   41.1 (5.6)        41.4 (5.8)      38.6 (4.6)      \<0.001

   Phosphate (mmol/L)                     376   1.1 (0.3)         1.1 (0.3)       1.2 (0.3)       0.068

   Parathyroid hormone (PTH) (pg/mL)      162   130.6(129.1)      109.8 (95.1)    230.3 (199.6)   \<0.001

   Total cholesterol (mmol/L)             192   4.6 (1.4)         4.6 (1.4)       4.5 (1.1)       0.783

   LDL cholesterol (mmol/L)               124   2.6(1.2)          2.6(1.2)        2.1(0.6)        0.106

   HDL cholesterol (mmol/L)               126   1.4(0.5)          1.4(0.5)        1.3(0.4)        0.728

   Triglycerides (mmol/L)                 190   4.0(21.6)         3.1(17.3)       2.6(1.7)        0.005

   HbA1c (mmol/mol)                       79    51.6(21.1)        52.5(22.0)      52.5(17.8)      0.850

  **Urine tests**                                                                                 

   Protein: creatinine ratio              136   136.0(246.8)      116.1(173.8)    323.4(571.3)    0.009

   Albumin: creatinine ratio              51    101.9(214.9)      116.8(233.9)    38.4(33.2)      0.999

  **Medications (%)**                                                                             

   ACE-I                                  114   (21.8)            93 (23.7)       17 (21.8)       0.772

   ARB                                    93    (17.8)            75 (19.1)       15 (19.2)       0.999

   ACE-I & ARB                            11    (2.1)             9 (2.3)         2 (2.6)         0.999

   ACE-I or ARB                           196   (37.5)            159 (40.5)      30 (38.5)       0.801

   Aspirin                                169   (32.4)            133 (33.8)      31 (39.7)       0.363

   Alpha Blocker                          18    (3.4)             17 (4.3)        0 (0.0)         0.089

   Beta Blocker                           147   (28.2)            108 (27.5)      34 (43.6)       0.007

   Calcium blocker                        152   (29.1)            126 (32.1)      21 (26.9)       0.423

   Diuretic                               121   (23.2)            84 (21.4)       35 (44.9)       \<0.001

   Statin                                 169   (32.4)            140 (35.6)      26 (33.3)       0.795

  **Gout-specific Medications (%)**                                                               

  *Urate-lowering therapies*              53    (10.2)            0 (0.0)         53 (67.9)       \<0.001

   Allopurinol                            49    (9.4)             0 (0.0)         49 (62.8)       \<0.001

   Febuxostat                             4     (0.8)             0 (0.0)         4 (5.1)         0.001

   Probenecid                             0     0                 0               0               NA

  *Acute flare/flare prophylaxis*                                                                 

   Colchicine                             4     (0.8)             0 (0.0)         4 (5.1)         0.001

   Corticosteroid                         21    (4.0)             15 (3.8)        6 (7.7)         0.136

   NSAIDs                                 4     (0.8)             3 (0.8)         0 (0.0)         0.999
  ---------------------------------------------------------------------------------------------------------

PKD, polycystic kidney disease; BP, blood pressure; LDL, low-density lipoprotein; HDL, high-density lipoprotein; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker: NSAIDs, Nonsteroidal anti-inflammatory drugs; eGFR, estimated glomerular filtration rate was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.

Gout-specific medications {#sec013}
-------------------------

Overall, 67.9% of patients with gout were receiving ULT as shown in [Table 2](#pone.0210487.t002){ref-type="table"} and the prevalence of ULT use increased from 55.6% in Stages 1--2 to 58.6 % in Stage 3 and to 77.4 % in Stages 4--5 (p = 0.002). Allopurinol was the most commonly prescribed ULT (62.8%) with a much smaller percentage treated with Febuxostat (5.1%). Colchicine use was recorded in 5.1% of patients while a further 7.7% of gout patients were receiving corticosteroids. None of the patients with gout were recorded as using non-steroidal anti-inflammatory drugs (NSAIDS).

Correlates of gout {#sec014}
------------------

The relationship of demographic and clinical factors with gout is illustrated in [Table 3](#pone.0210487.t003){ref-type="table"}. With adjustment only for age and sex; advancing age \[1.11 (95% CI 1.02--1.20) for every 5-year increase\], male gender \[OR 1.85 (1.09--3.12)\] and patients with coronary disease \[OR 1.94 (1.05--3.58)\] were significantly more likely to have gout. Worsening kidney function increased the likelihood of having gout \[OR 1.10 (1.03--1.17) for each 5 ml/min/1.73m^2^ decrease in eGFR\]. Similarly, higher levels of proteinuria quantified by protein/creatinine ratio estimation were correlated with greater likelihood of gout \[log~2~ PCR 1.45 (1.09--1.93), p\<0.05). Lower serum albumin levels and worsening secondary hyperparathyroidism were also associated with greater likelihood of gout \[OR 1.09 (1.03--1.14) per 1 g/dL decrease in albumin, and OR 1.33 (1.14--1.56) per 50 pg/mL increase in PTH, all p \<0.005. Use of diuretics and beta-blockers also correlated with gout \[OR 2.72 (1.61--4.60) and OR 1.81 (1.08--3.02) respectively.

10.1371/journal.pone.0210487.t003

###### Unadjusted, and age- and sex-adjusted Odd Ratios and 95% confidence intervals for gout.

![](pone.0210487.t003){#pone.0210487.t003g}

  Variable                                   N     OR (95% CI)         P-value   N     AOR (95% CI)[^1^](#t003fn002){ref-type="table-fn"}   P-value
  ------------------------------------------ ----- ------------------- --------- ----- ---------------------------------------------------- ---------
  **Demographics**                                                                                                                          
   Age per 5 year increase                   471   1.11 (1.02--1.2)    0.012     469   1.11 (1.02--1.2)                                     0.013
   Male vs Female                            469   1.86 (1.11--3.13)   0.019     469   1.85 (1.09--3.12)                                    0.022
  **Comorbid Conditions**                                                                                                                   
   Diabetes                                  469   1.15 (0.65--2.03)   0.634     467   0.95 (0.52--1.71)                                    0.851
   Hypertension                              469   1.26 (0.68--2.37)   0.463     467   1.14 (0.6--2.16)                                     0.682
   Cancer                                    469   1.14 (0.46--2.87)   0.777     467   0.89 (0.35--2.29)                                    0.813
   Heart failure                             468   0.79 (0.23--2.75)   0.716     466   0.66 (0.19--2.32)                                    0.519
   Thyroid disease                           469   0.70 (0.29--1.72)   0.441     467   0.67 (0.27--1.67)                                    0.388
   Stroke or Transient ischaemic attack      469   0.23 (0.03--1.75)   0.157     467   0.21 (0.03--1.57)                                    0.127
   Chronic obstructive airways disease       469   1.14 (0.37--3.46)   0.819     467   1.07 (0.35--3.3)                                     0.910
   Peripheral vascular disease               469   0.95 (0.38--2.36)   0.913     467   0.69 (0.27--1.75)                                    0.438
   Coronary heart disease                    468   2.61 (1.47--4.63)   0.001     466   1.94 (1.05--3.58)                                    0.034
   Obesity                                   469   1.42 (0.56--3.63)   0.462     467   1.21 (0.47--3.13)                                    0.694
   Hypercholesterolaemia                     468   1.01 (0.58--1.75)   0.977     466   0.90 (0.52--1.58)                                    0.725
   Depression                                469   0.88 (0.3--2.62)    0.817     467   0.80 (0.26--2.42)                                    0.690
   Arthritis                                 469   1.02 (0.38--2.75)   0.970     467   0.97 (0.35--2.68)                                    0.960
   Osteoporosis                              469   0.92 (0.41--2.03)   0.831     467   0.95 (0.42--2.12)                                    0.892
  **Laboratory Variables**                                                                                                                  
   eGFR per 5 ml/min/1.73m^2^ decrease       419   1.11 (1.04--1.18)   0.001     419   1.10 (1.03--1.17)                                    0.005
   Haemoglobin per 1 g/dL increase           413   0.96 (0.83--1.1)    0.530     411   0.98 (0.85--1.14)                                    0.838
   Ferritin per 1 ng/L increase              151   1.00 (1.00--1.00)   0.450     151   1.00 (1.00--1.00)                                    0.520
   TSAT ratio per 1% increase                121   0.97 (0.92--1.01)   0.167     121   0.97 (0.93--1.02)                                    0.271
   Folate per 1 nmol/L increase              92    1.00 (1.00--1.00)   0.631     92    1.00 (1.00--1.00)                                    0.499
   Vitamin B12 per 1 nmol/L increase         114   1.00 (1.00--1.00)   0.796     114   1.00 (1.00--1.00)                                    0.892
   Calcium (mmol/L)                          373   0.56 (0.1--3.04)    0.504     371   0.83 (0.14--4.73)                                    0.830
   Serum Albumin per 1 g/L decrease          327   1.08 (1.03--1.13)   0.002     325   1.09 (1.03--1.14)                                    0.001
   Phosphate per 1 mmol/L increase           346   2.57 (0.97--6.83)   0.059     344   2.43 (0.87--6.81)                                    0.091
   PTH per 50 pg/mL increase                 157   1.34 (1.15--1.57)   \<0.001   156   1.33 (1.14--1.56)                                    \<0.001
   Total cholesterol per 1 mmol/L increase   181   0.92 (0.64--1.32)   0.652     180   1.01 (0.69--1.47)                                    0.976
   LDL cholesterol per 1 mmol/L increase     118   0.55 (0.27--1.15)   0.112     117   0.55 (0.26--1.15)                                    0.114
   HDL cholesterol per 1mmol/L increase      120   0.63 (0.17--2.38)   0.495     119   0.65 (0.16--2.66)                                    0.545
   Triglycerides per 1 mmol/L increase       179   1.00 (0.96--1.03)   0.888     178   1.00 (0.96--1.03)                                    0.837
   HbA1c per 1 mmol/mol increase             75    1.00 (0.97--1.03)   0.993     75    1.00 (0.97--1.03)                                    0.961
   log~2~(PCR)                               125   1.43 (1.08--1.9)    0.012     124   1.45 (1.09--1.93)                                    0.011
  **Medications**                                                                                                                           
   ACE-I                                     471   0.90 (0.50--1.61)   0.722     469   0.87 (0.48--1.6)                                     0.665
   ARB                                       471   1.01 (0.54--1.87)   0.976     469   1.19 (0.63--2.25)                                    0.594
   Aspirin                                   471   1.29 (0.78--2.12)   0.318     469   0.94 (0.55--1.61)                                    0.829
   Beta Blocker                              471   2.04 (1.24--3.36)   0.005     469   1.81 (1.08--3.02)                                    0.023
   Calcium blocker                           471   0.78 (0.45--1.34)   0.372     469   0.72 (0.41--1.25)                                    0.243
   Diuretic                                  471   2.99 (1.80--4.97)   \<0.001   469   2.72 (1.61--4.60)                                    \<0.001
   Statin                                    471   0.90 (0.54--1.51)   0.699     469   0.76 (0.45--1.29)                                    0.306

LDL, low-density lipoprotein; HDL, high-density lipoprotein; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker: NSAIDs, Nonsteroidal anti-inflammatory drugs; eGFR, estimated glomerular filtration rate was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI).

^1^AOR: adjusted for age and sex only

In the fully adjusted model, lower eGFR and worsening serum albumin remained significant correlates of gout as illustrated in [Table 4](#pone.0210487.t004){ref-type="table"}. Given that PTH values were available for a smaller percentage of patients (n = 162), an additional analysis was performed in which we restricted to the final model to those with valid PTH concentrations. In this restricted model, a rising PTH concentration was also significant \[OR 1.38, (1.08--1.77) per 50 pg/mL increase, p = 0.01. This model had a C-statistic of 0.83.

10.1371/journal.pone.0210487.t004

###### Multivariable Odds Ratio for gout among patients with CKD in the Irish health system.
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  Variable                                    AOR (95% CI)        P-value   AOR (95% CI)         P-value
  ------------------------------------------- ------------------- --------- -------------------- ---------
  Age per 5 year increase                     1.09 (0.96--1.24)   0.185     1.00 (0.82--1.21)    0.962
  Male vs Female                              1.95 (0.95--4.03)   0.070     2.99 (0.79--11.33)   0.107
  Coronary Heart Disease                      1.57 (0.68--3.63)   0.291     1.47 (0.37--5.76)    0.583
  Diuretic use                                1.79 (0.87--3.68)   0.111     0.78 (0.20--2.95)    0.710
  eGFR per 5 ml/min/1/73m^2^ decrease         1.11 (1.01--1.22)   0.037     1.03 (0.85--1.23)    0.792
  Serum albumin per 1 g/L decrease            1.09 (1.02--1.16)   0.008     1.15 (1.01--1.30)    0.040
  Serum phosphate per 1 mmol/l increase       0.34 (0.08--1.46)   0.147     0.40 (0.04--4.20)    0.445
  Parathyroid hormone per 50 pg/mL increase                       --        1.38 (1.08--1.77)    0.011

Model 1: adjusted for continuous variables (age, eGFR, serum albumin, serum phosphate) and categorical variables (sex, history of coronary heart disease and diuretic use). The model had a C-statistic 0.77 and there was no evidence of poor fit from the Hosmer and Lemeshow goodness of fit test (p = 0.6). Model 2: adjusted for all variables as Model 1 in addition to serum parathyroid hormone (PTH). This model had a C-statistic of 0.83 and there was no evidence of poor fit from the Hosmer and Lemeshow goodness of fit test (p = 0.9).

Discussion {#sec015}
==========

In this large multi-centre study, we found a substantial burden of gout among Irish patients with CKD (16.6%) that increased significantly from 7.5% in patients with mild CKD to 22.8% among patients with moderate to severe CKD (eGFR \< 30 ml/min/1.73m^2^). Gout was more common in men than in women and rates increased with advancing age. Adjusting for differences in age and sex, we found that patients with lower kidney function, lower serum albumin, and worsening secondary hyperparathyroidism were more likely to have gout. Overall, almost 68% of gout patients with CKD were receiving ULT agents, with allopurinol being the most commonly prescribed ULT. Importantly and encouragingly, we observed a significant trend of increasing ULT use from 55.6% in Stage 1--2 to 77.4% in Stage 4--5, evidence that supports better recognition and treatment of gout in this high-risk population.

Recent studies have identified strong relationships between gout and CKD, which are not surprising given that hyperuricaemia, the principal driver of gout, is an inevitable consequence of worsening kidney function \[[@pone.0210487.ref017]\]. However, only few have quantified the burden of gout and corresponding rates of ULT treatment among patients with pre-existing CKD. In our study, we describe a substantial burden of gout in CKD patients attending specialist clinics in the Irish health system. Our estimate (16.6%) is somewhat lower than that reported by the German Chronic Kidney Disease study (24.3%), which may reflect underlying differences in prevalence in the general population from respective countries or differences in rates of death among gout patients with CKD \[[@pone.0210487.ref013]\]. However, the pattern of increase in gout prevalence from early CKD to advanced CKD followed near identical trends in both studies with an approximately 3-fold rise in prevalence. These results suggest that at the very least that gout is an extremely common but treatable comorbidity among CKD patients who are already under clinical surveillance in the health system.

Our study provides novel insights into the range and extent of treatment strategies for patients with gout managed by kidney specialists in the Irish health system. We report overall treatment rates of 68% for ULT among gout patients with CKD, which are identical to those reported by the German CKD cohort (67%). However, unlike Germany, the principal ULT in Ireland were uricostatic (predominantly allopurinol), as no patient was recorded as receiving uricosuric therapy. Encouragingly, we reveal that rates of ULT use have increased from 55.6% among patients in CKD stage 1--2 to 77.4% for patients with more advanced CKD 4--5 suggesting a propensity to greater ULT prescribing. This trend in prescribing patterns may reflect the increasing recognition by kidney specialists in Ireland that gout is eminently treatable or that gout and/or hyperuricaemia are emerging risk factors for CKD progression \[[@pone.0210487.ref007]--[@pone.0210487.ref011]\]. It is equally noteworthy, that colchicine (5.1%) and corticosteroids (7.7%) were the standard therapies for acute flare or flare prophylaxis with no recorded use of NSAIDs. This new data highlights a positive practice pattern that supports avoidance of nephrotoxic medications and kidney function preservation \[[@pone.0210487.ref015]\].

Despite the moderately high proportion of CKD patients with gout receiving ULT therapy in this study, a substantial proportion of patients (\~32%) nevertheless were untreated. Studies have consistently shown that the treatment of gout is suboptimal in the general population \[[@pone.0210487.ref018]\]. Prescription rates of ULT vary substantially from as low as 23% (Taiwan), 38% (UK) and 42% (Sweden) to a spectacular 80% in South Korea \[[@pone.0210487.ref019]--[@pone.0210487.ref021]\]. Low treatment rates among patients with CKD may be partially explained by the presence of absolute and relative contraindications to the medications, as well as a lack of drug efficacy \[[@pone.0210487.ref022]\]. Additionally, dietary and lifestyle interventions may account for those not undertaking ULT. Dietary modification is typically suggested as part of the initial treatment for patients with gout, although some suggest it should be ancillary to ULT \[[@pone.0210487.ref023]\]. Prior to the availability of febuxostat, allopurinol was the principal ULT for patients with gout and impaired renal function. However, the risk of allopurinol hypersensitivity syndrome (AHS) is increased in renal impairment and consequently lingering concerns regarding this infrequent but potentially lethal event may contribute to ULT avoidance in CKD patients \[[@pone.0210487.ref024],[@pone.0210487.ref025]\].

Prior studies have identified strong relationships between hyperuricaemia, the precursor to gout, and several metabolic markers \[[@pone.0210487.ref026]\]. In the current study, we observed for the first time an inverse relationship between serum albumin and gout. In the final adjusted model, for each 1 g/L lower serum albumin, the likelihood of gout increased by 9%. Low serum albumin may reflect protein-losing states, poor nutritional status, or systemic inflammation. Prior studies have also identified an independent relationship between serum uric acid and the extent of albuminuria \[[@pone.0210487.ref027]--[@pone.0210487.ref030]\]. Tseng and colleagues have reported positive increases in urinary albuminuria with increasing serum uric acid concentrations in type 2 diabetes \[[@pone.0210487.ref027]\] while prospectively designed cohorts have confirmed the predictive impact of hyperuricaemia on albuminuria \[[@pone.0210487.ref028]--[@pone.0210487.ref030]\]. Serum albumin is a negative acute phase reactant, and thus low serum albumin levels may also reflect ongoing systemic inflammation associated with gout.

We also uncovered a very strong independent association between elevated PTH and the occurrence of gout. This is an intriguing finding, which suggests that progressive secondary hyperparathyroidism serves to increase the likelihood of gout in the setting of CKD. Previous studies have suggested a strong biological influence of PTH on serum uric acid levels possibly mediated by reduced renal excretion of uric acid \[[@pone.0210487.ref031]--[@pone.0210487.ref035]\]. However, in virtually all of these studies, hyperparathyroidism was primary in nature, and correction of which led to a fall in uric acid concentrations \[[@pone.0210487.ref031],[@pone.0210487.ref032]\]. Our study not only extends the observations of previous instigators but for the first time associates secondary hyperparathyroidism of CKD with clinical gout. Indeed in our analysis, a rising serum PTH level was a stronger correlate of gout than worsening eGFR, suggesting a strong pathobiological basis.

Our study is not with limitations. *First*, the design of the study was cross-sectional in nature with reliance on medical records for data extraction. Therefore, we cannot infer causality between explanatory covariates and gout. *Second*, although joint aspiration for monosodium urate crystals remains the gold standard for diagnosis in clinical practice, our study relied on a clinical diagnosis from medical records based on physician-diagnosis and/or use of ULT. Inclusion of ULT medications ensured greater capture of clinical gout that may not have been recorded on the patient's medical record. *Third*, we lacked data on serum uric acid concentrations, and thus were unable to correlate gout or ULT use with target thresholds. Notwithstanding these limitations, the study was multicentre, with participation from a diverse range of nephrology clinics across Ireland, thus strengthening the generalisability. Although a probability sampling strategy would have been preferred, we argue that the application of consecutive sampling to a homogenous population, attending renal clinics across multiple sites reduces bias in relation to the representativeness of the study population. The large sample included a detailed description of patient characteristics including comorbid conditions, measures of kidney function including proteinuria. Finally, our analysis included a detailed description of current prescribed ULT medications as well as medications for acute flares and flare prophylaxis.

Conclusion {#sec016}
==========

In conclusion, our findings demonstrate a substantial burden of gout among patients with CKD in the Irish health system that increases with advancing CKD. Male gender, worsening kidney function, malnutrition and secondary hyperparathyroidism were identified as independent correlates. Almost 68% of patients with CKD were receiving ULT that increased to 77% among patients with Stage 4--5 CKD. Patients with both gout and CKD represent a high-risk group for considerable morbidity and mortality, compounded by the individual contribution of each to adverse clinical outcomes. Given the substantial burden of gout in CKD patients, greater awareness, screening and treatment of gout are key to improving patient outcomes in this population. Future studies should examine dosing of ULT among CKD patients and the extent to which treatment targets are achieved in order to prevent the complications of gout and potentially slow the progression of CKD.
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